Tree Man Syndrome: Understanding a Rare Genetic Disorder Beyond the Stigma

Epidermodysplasia Verruciformis arrives quietly in childhood and never leaves. The condition, known colloquially as Tree Man Syndrome, begins with flat, scaly patches on the skin that harden and thicken over years, eventually resembling bark so closely that the comparison is not metaphorical but descriptive. According to Dr. Ajay Rana, a dermatologist and founder of ILAMED, the disorder stems from mutations in genes TMC6 or TMC8—mutations that cripple the body's ability to mount an immune response against certain strains of human papillomavirus, particularly the beta variants. The growths spread across hands, feet, face, and torso, accumulating weight and rigidity as time passes.

Diagnosis itself is a labyrinth. There is no single test that confirms the condition. Instead, clinicians piece together evidence from clinical examination, skin biopsy, HPV testing, and genetic sequencing. The lesions typically surface in early childhood and worsen steadily with age, which means a child diagnosed at five will face a lifetime of progressive deterioration. Once identified, the condition offers no permanent cure. Treatment amounts to management: surgical removal of growths, topical retinoid applications, and experimental antiviral approaches. The surgeries, however, provide only temporary relief. The lesions return. And because patients with EV carry substantially elevated risk for skin cancer, regular monitoring becomes not optional but essential—a lifelong medical obligation.

Misunderstanding surrounds the condition like fog. The appearance of the growths—their alien, almost alien quality—invites the assumption that the condition spreads through contact, that it results from poor hygiene or negligence. Neither is true. EV is purely genetic. The HPV strains involved do not behave like typical infections that move from person to person. They only become pathogenic in individuals carrying the faulty genes. Dr. Rana emphasizes this distinction sharply: the condition cannot be caught, cannot be prevented through cleanliness, cannot be transmitted. It is inherited, not acquired. Yet in communities where literacy is low or superstition runs high, this distinction dissolves. Patients have faced violence, have been accused of witchcraft, have been driven into isolation by neighbors who fear contagion that does not exist.

Prevention, in the traditional sense, is impossible. A person born with mutations in TMC6 or TMC8 will develop the condition if they inherit those mutations. Genetic counseling can inform families about risks for future generations, but it cannot erase the genetic code already written. Early detection and consistent medical monitoring can reduce complications—particularly the threat of malignancy—but they cannot stop the disease itself.

The lived experience of EV is multidimensional suffering. The physical pain intensifies as lesions grow heavier and more extensive, constraining movement and basic function. The psychological weight is equally severe: anxiety, depression, and the grinding frustration of a chronic condition that worsens over time. Fewer than 600 cases have been documented worldwide, a rarity that compounds the problem. Misdiagnosis is common. Specialized care is scarce. In India, where cases are even rarer, rural patients often have no access to dermatologists equipped to recognize or treat the condition. The combination of medical scarcity, social stigma, and misinformation creates an environment where patients suffer not only from the disease but from isolation, neglect, and in some cases, community-driven harm. Dr. Rana's closing statement carries the weight of clinical observation and moral clarity: people living with EV should not be stigmatized or isolated. The statement is simple because it needs to be. The reality it addresses is not.